NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced the completion of its previously announced public offering of 9,600,000 shares of common stock. In connection with the closing, Barclays Capital Inc., the sole book-running manager for the offering, exercised in full its option to purchase an additional 1,440,000 shares, resulting in ZIOPHARM issuing a total of 11,040,000 shares in the offering. The net proceeds from this offering were approximately $59.4 million after deducting underwriting discounts and commissions and estimated offering expenses.
